India, Feb. 26 -- As India accelerates its ambitions in biologics and biosimilars, the country's next growth phase will be driven not just by infrastructure, but by capability building and process excellence said Dr Uma Sinha Datta, Director - Process Development at Cytiva India.

Speaking about the evolving biopharma landscape, Dr Uma emphasised that while India has long been recognised for its strength in generics and vaccines, biologics demand a fundamentally different ecosystem. "Biopharma manufacturing is science-intensive and skill-intensive. It requires hands-on training, exposure to advanced equipment, and deep understanding of both upstream and downstream processes," she said.

At the core of Cytiva India's strategy is its Fast T...